Mark P. Lappe - 29 May 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: INBX
Reported as of: 29 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 May 2024, 18:10:50 UTC
Prior SEC filing: 24 May 2024
Next SEC filing: 30 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Kelly D. Deck, Chief Financial Officer of Inhibrx Biosciences, Inc., attorney-in-fact

Key filing fact

Mark P. Lappe filed Form 4 for Inhibrx Biosciences, Inc. (INBX) on 30 May 2024.

Key facts

This page summarizes Mark P. Lappe's Form 4 filing for Inhibrx Biosciences, Inc. (INBX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 May 2024, 18:10.

Change

Previous filing in this sequence was filed on 24 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INXB transaction

Common Stock

Award

Transaction value
Shares: +621,548
Change %
Price
Shares after: 621,548
Date: 29 May 2024
Ownership: By the Lappe Family Trust
Footnotes: F1, F2

INXB transaction

Common Stock

Award

Transaction value
Shares: +125,000
Change %
Price
Shares after: 125,000
Date: 29 May 2024
Ownership: By trust
Footnotes: F1, F3

INXB transaction

Common Stock

Award

Transaction value
Shares: +14,865
Change %
Price
Shares after: 14,865
Date: 29 May 2024
Ownership: The Mark Paul Lappe Roth IRA
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INXB transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 30 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $15.86
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.

Footnote F2

These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.

Footnote F3

These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.

Footnote F4

This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.

Footnote F5

Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.